Management

Hans Jeppsson has been the CFO since 2017 and has a cross-disciplinary background in finance and medicine. He has previously worked as a biotech analyst at Danske Bank as well as within preclinical research at AstraZeneca R&D.

Shareholdings: View shareholding in link

Options: 190,000

Education: Ph.D. in Business Administration from the University of Gothenburg. After he obtained his Ph.D.-degree he conducted postdoctoral studies at the Haas School of Business at the UC Berkeley in the US. He also has a background in chemical engineering with a focus on biotechnology from Chalmers University of Technology.

Johan Raud has been the CSO since 2018 with more than 20 years of experience from heading research teams and managing drug discovery projects in both big pharma and startups. Johan gained his MD, PhD and Associate Professorship at Karolinska Institutet and Vanderbilt University.

Shareholdings: View shareholding in link

Options: 145,000

Education: MD PhD from the Karolinska Institute and Vanderbilt university, USA

Mikael Nygård has been VP Operations and Corporate Strategy since 2024 and previously he led the Business Development activities in Vicore. He has extensive experience from Business Development in the healthcare industry. He has led M&A and Corporate Development at the care provider Humana AB and has also worked in the global healthcare team at the strategy consulting firm Boston Consulting Group.

Shareholdings: View shareholding in link

Options: 161,000

Education: MSc Pharmacy, Uppsala University. PhD Neurobiology, Karolinska Institutet.

Jimmie Hofman has been VP Business Development since 2024. He is an experienced deal maker in the life science industry, with extensive experience in business development, corporate strategy, and financial modeling. Prior to joining Vicore, Jimmie was Senior Director, Business Development at Pieris Pharmaceuticals, where he was responsible for business development activities, and part of establishing strategic partnerships with multiple pharmaceutical companies, including AstraZeneca, Roche/Genentech, Seagen, Servier, and Boston Pharmaceuticals.

Shareholdings: View shareholding

Options: 50,000

Education: B.Sc. Bioengineering, M.Sc. Entrepreneurship & Business Design, Intellectual Capital Management from Chalmers University of Technology

Helen is a pharmaceutical scientist and business leader, with over 25 years of experience delivering the technical and strategic development of novel compounds, devices and companies.

Shareholdings: View shareholding

Options: –

Education: B.Sc. in Chemical and Pharmaceutical Science, University of Sunderland.

Professor Bertil Lindmark has been the CMO since 2024 and has a long career within the pharmaceutical industry with demonstrated expertise within respiratory and inflammatory diseases.  Bertil has held global roles within AstraZeneca, leading the development of global brands like Pulmicort and Symbicort. He was the Head of Research and Development at Almirall, leading the development of the second to market inhaled long acting antimuscarinic, aclidinium bromide. Bertil also held CMO roles in biotech companies, ASLAN Pharmaceuticals, eTheRNA Immunotherapies, and Galecto, where his leadership played a crucial role in driving innovation and advancing pharmaceutical development of both oncology compounds, liver disease compounds and IPF directed therapies. Bertil Lindmark is Professor Emeritus at the University of Gothenburg, chairs the scientific committee at the Board of ALK, and is the Chairman of the Board at Aqilion.

Shareholdings:View shareholding

Options: 125,000

Education: MD PhD from Lund University, Sweden.